BMS-214662

DRUG6 trials

Sponsors

Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Case Comprehensive Cancer Center

Conditions

Adult Acute Promyelocytic Leukemia (M3)Blastic Phase Chronic Myelogenous LeukemiaChildhood Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid Leukemia

Phase 1

BMS-214662 in Treating Patients With Solid Tumors

CompletedNCT00005973

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific

Start: 2000-04-30Updated: 2013-01-23

BMS-214662 in Treating Patients With Advanced Solid Tumors

CompletedNCT00006242

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2000-07-31Updated: 2013-02-01

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

CompletedNCT00022529

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2001-07-31Updated: 2013-01-25

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

CompletedNCT00006213

National Cancer Institute (NCI)Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes +8

Start: 2000-04-30Updated: 2013-01-23

Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors

CompletedNCT00006018

Case Comprehensive Cancer CenterUnspecified Adult Solid Tumor, Protocol Specific

Start: 2000-07-31End: 2002-04-30Updated: 2010-06-11

BMS-214662 in Treating Patients With Advanced Solid Tumors

CompletedNCT00004877

Memorial Sloan Kettering Cancer CenterUnspecified Adult Solid Tumor, Protocol Specific

Start: 1999-07-31Updated: 2009-12-03